LAG3 and neoplasm: At present, numerous clinical trials investigate the efficacy of LAG3 blockage, enrolling patients with a broad spectrum of neoplastic diseases (e.g., head and neck carcinomas, melanoma, colorectal carcinoma, NSCLC: NCT01968109).